This segment focuses on the research and development of therapeutics for sensorineural hearing loss (SNHL). The primary focus is on FX-322, a small-molecule therapeutic designed to activate progenitor cells in the inner ear to regenerate hair cells, the sensory cells responsible for hearing. Research and development activities include preclinical studies, Phase 1 and Phase 2 clinical trials, and manufacturing process development. The company utilizes advanced molecular biology and drug discovery techniques to identify and optimize small molecules. The goal is to improve hearing function and quality of life for individuals with SNHL. Market positioning is based on addressing a significant unmet medical need with a novel regenerative approach. Partnerships with Astellas Pharma Inc. support the commercialization efforts. Future opportunities include expanding the therapeutic applications to other forms of hearing loss and other degenerative conditions.

This segment encompasses research and development efforts targeting remyelination in multiple sclerosis (MS) and other degenerative conditions. The company is exploring the potential of its progenitor cell activation approach to repair or reverse damage caused by these diseases. Research activities include preclinical studies, clinical trials, and the identification of novel therapeutic targets. The company is leveraging its expertise in small molecule drug discovery and regenerative medicine to develop treatments that address the underlying causes of these conditions. The goal is to improve patient outcomes and slow or halt disease progression. This segment is positioned to address significant unmet medical needs in neurology and other therapeutic areas. The company is actively seeking partnerships and collaborations to advance its programs. Future opportunities include expanding the pipeline to address a broader range of degenerative diseases.